ABBV
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
- —
- Total sold
- —
- Last activity
- —
- Last synced
-
2026-08-04 10:23:03
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-03
ABBV presents a structurally weak financial profile with a liquidity score of 30 and fundamental trend score of 35, reflecting negative working capital, a debt-to-capital ratio exceeding 1.0, and declining net margins…
The first sentence of the analysis written for ABBV on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | |
| Ebit Margin | 15.5% | 11.6% | 15.6% | 27.1% | 27.4% | |
| Ebitda Margin | 28.8% | 26.5% | 31.6% | 41.6% | 42.6% | |
| Operating Profit Margin | 32.8% | 16.2% | 23.5% | 31.2% | 31.9% | |
| Pretax Profit Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | |
| Continuous Operations Profit Margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.6% | |
| Net Profit Margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | |
| Bottom Line Profit Margin | 6.9% | 7.5% | 8.9% | 20.3% | 20.4% | |
| Current Ratio | 0.671 | 0.660 | 0.872 | 0.964 | 0.794 | |
| Quick Ratio | 0.557 | 0.552 | 0.764 | 0.842 | 0.705 | |
| Solvency Ratio | 0.090 | 0.096 | 0.109 | 0.167 | 0.153 | |
| Cash Ratio | 0.121 | 0.143 | 0.339 | 0.311 | 0.277 | |
| Price To Earnings Ratio | 96.409 | 74.042 | 56.766 | 24.302 | 20.895 | |
| Price To Earnings Growth Ratio | -77.127 | -6.125 | -0.963 | 9.263 | 0.152 | |
| Forward Price To Earnings Growth Ratio | -77.127 | -6.125 | -0.963 | 9.263 | 0.152 | |
| Price To Earnings Diluted Ratio | 96.409 | 74.351 | 56.974 | 24.376 | 20.992 | |
| Price To Earnings Diluted Growth Ratio | -115.209 | -6.128 | -0.966 | 8.735 | 0.153 | |
| Price To Book Ratio | -124.404 | 94.542 | 26.447 | 16.588 | 15.554 | |
| Price To Sales Ratio | 6.651 | 5.580 | 5.044 | 4.930 | 4.265 | |
| Price To Free Cash Flow Ratio | 22.834 | 17.628 | 12.419 | 11.804 | 10.898 | |
| Price To Operating Cash Flow Ratio | 21.377 | 16.715 | 11.996 | 11.475 | 10.522 | |
| Debt To Assets Ratio | 0.516 | 0.502 | 0.446 | 0.462 | 0.529 | |
| Debt To Equity Ratio | -21.122 | 20.403 | 5.803 | 3.720 | 5.035 | |
| Debt To Capital Ratio | 1.050 | 0.953 | 0.853 | 0.788 | 0.834 | |
| Long Term Debt To Capital Ratio | 1.058 | 0.948 | 0.834 | 0.774 | 0.806 | |
| Financial Leverage Ratio | -40.966 | 40.650 | 13.003 | 8.045 | 9.510 | |
| Working Capital Turnover Ratio | -4.465 | -6.257 | -18.369 | -13.920 | -9.562 | |
| Operating Cash Flow Ratio | 0.440 | 0.485 | 0.604 | 0.844 | 0.647 | |
| Operating Cash Flow Sales Ratio | 0.311 | 0.334 | 0.420 | 0.430 | 0.405 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.936 | 0.948 | 0.966 | 0.972 | 0.965 | |
| Debt Service Coverage Ratio | 1.311 | 1.610 | 1.678 | 3.451 | 1.490 | |
| Interest Coverage Ratio | 6.945 | 3.254 | 5.736 | 8.124 | 7.397 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.175 | 2.764 | 3.176 | 5.798 | 1.797 | |
| Operating Cash Flow Coverage Ratio | 0.276 | 0.277 | 0.380 | 0.389 | 0.294 | |
| Capital Expenditure Coverage Ratio | 15.675 | 19.308 | 29.394 | 35.889 | 28.942 | |
| Dividend Paid And Capex Coverage Ratio | 1.479 | 1.567 | 2.018 | 2.323 | 2.267 | |
| Dividend Payout Ratio | 2.758 | 2.577 | 2.167 | 0.849 | 0.802 | |
| Enterprise Value Multiple | 26.697 | 25.263 | 18.710 | 14.114 | 12.848 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.2% | ▲0.2% | ▲1.9% |
| Ebit Margin | 15.5% | ▲3.9% | ▼-3.9% |
| Ebitda Margin | 28.8% | ▲2.4% | ▼-5.4% |
| Operating Profit Margin | 32.9% | ▲16.6% | ▲5.7% |
| Pretax Profit Margin | 10.8% | ▲4.2% | ▼-4.3% |
| Continuous Operations Profit Margin | 6.9% | ▼-0.7% | ▼-6.0% |
| Net Profit Margin | 6.9% | ▼-0.7% | ▼-6.0% |
| Bottom Line Profit Margin | 6.9% | ▼-0.7% | ▼-5.9% |
| Current Ratio | 0.671 | ▲0.011 | ▼-0.121 |
| Quick Ratio | 0.557 | ▲0.005 | ▼-0.127 |
| Solvency Ratio | 0.090 | ▼-0.006 | ▼-0.033 |
| Cash Ratio | 0.121 | ▼-0.022 | ▼-0.117 |
| Price To Earnings Ratio | 96.409 | ▲22.368 | ▲41.926 |
| Price To Earnings Growth Ratio | -77.127 | ▼-71.002 | ▼-62.167 |
| Forward Price To Earnings Growth Ratio | -77.127 | ▼-71.002 | ▼-62.167 |
| Price To Earnings Diluted Ratio | 96.409 | ▲22.058 | ▲41.789 |
| Price To Earnings Diluted Growth Ratio | -115.209 | ▼-109.081 | ▼-92.526 |
| Price To Book Ratio | -124.404 | ▼-218.946 | ▼-130.149 |
| Price To Sales Ratio | 6.651 | ▲1.071 | ▲1.357 |
| Price To Free Cash Flow Ratio | 22.834 | ▲5.205 | ▲7.717 |
| Price To Operating Cash Flow Ratio | 21.377 | ▲4.661 | ▲6.960 |
| Debt To Assets Ratio | 0.516 | ▲0.014 | ▲0.025 |
| Debt To Equity Ratio | -21.122 | ▼-41.525 | ▼-23.890 |
| Debt To Capital Ratio | 1.050 | ▲0.096 | ▲0.154 |
| Long Term Debt To Capital Ratio | 1.058 | ▲0.110 | ▲0.174 |
| Financial Leverage Ratio | -40.966 | ▼-81.616 | ▼-47.015 |
| Working Capital Turnover Ratio | -4.465 | ▲1.792 | ▲6.050 |
| Operating Cash Flow Ratio | 0.440 | ▼-0.046 | ▼-0.164 |
| Operating Cash Flow Sales Ratio | 0.311 | ▼-0.023 | ▼-0.069 |
| Free Cash Flow Operating Cash Flow Ratio | 0.936 | ▼-0.012 | ▼-0.021 |
| Debt Service Coverage Ratio | 1.311 | ▼-0.299 | ▼-0.597 |
| Interest Coverage Ratio | 6.945 | ▲3.691 | ▲0.653 |
| Short Term Operating Cash Flow Coverage Ratio | 2.175 | ▼-0.589 | ▼-0.967 |
| Operating Cash Flow Coverage Ratio | 0.276 | ▼-0.002 | ▼-0.047 |
| Capital Expenditure Coverage Ratio | 15.675 | ▼-3.633 | ▼-10.166 |
| Dividend Paid And Capex Coverage Ratio | 1.478 | ▼-0.089 | ▼-0.452 |
| Dividend Payout Ratio | 2.758 | ▲0.181 | ▲0.928 |
| Enterprise Value Multiple | 26.697 | ▲1.434 | ▲7.170 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $406.80B | $314.35B | $273.99B | $286.21B | $239.66B | |
| Enterprise value | $470.64B | $376.67B | $321.29B | $341.20B | $307.49B | |
| EV / Sales | 7.70x | 6.69x | 5.92x | 5.88x | 5.47x | |
| EV / Op. cash flow | 24.73x | 20.03x | 14.07x | 13.68x | 13.50x | |
| EV / Free cash flow | 26.42x | 21.12x | 14.56x | 14.07x | 13.98x | |
| EV / EBITDA | 26.70x | 25.26x | 18.71x | 14.11x | 12.85x | |
| Net debt / EBITDA | 3.62x | 4.18x | 2.75x | 2.27x | 2.83x | |
| Current ratio | 0.67x | 0.66x | 0.87x | 0.96x | 0.79x | |
| Income quality | 4.50x | 4.39x | 4.74x | 2.11x | 1.97x | |
| Graham number | — | $10 | $19 | $38 | $36 | |
| Graham net-net | -$67 | -$66 | -$57 | -$58 | -$63 | |
| Tax burden | 64.1% | 115.1% | 77.8% | 87.8% | 88.9% | |
| Interest burden | 69.5% | 57.0% | 73.8% | 85.8% | 84.3% | |
| Working capital | -$14.23B | -$13.17B | -$4.84B | -$1.07B | -$7.27B | |
| Invested capital | $80.42B | $86.99B | $88.05B | $103.45B | $106.17B | |
| Return on assets | 3.2% | 3.2% | 3.6% | 8.5% | 7.9% | |
| Operating ROA | 14.9% | 6.8% | 9.3% | 12.7% | 12.1% | |
| Return on tangible assets | 9.3% | 10.7% | 10.4% | 30.2% | 30.2% | |
| Return on equity | -129.2% | 128.7% | 46.9% | 68.6% | 74.9% | |
| Return on invested capital | 13.0% | 8.9% | 9.6% | 14.0% | 12.9% | |
| Return on capital employed | 22.2% | 9.5% | 13.2% | 16.6% | 16.1% | |
| Earnings yield | 1.0% | 1.4% | 1.8% | 4.1% | 4.8% | |
| Free cash flow yield | 4.4% | 5.7% | 8.1% | 8.5% | 9.2% | |
| Capex / Op. cash flow | 6.4% | 5.2% | 3.4% | 2.8% | 3.5% | |
| Capex / Depreciation | 14.9% | 11.6% | 8.9% | 8.2% | 9.2% | |
| Capex / Sales | 2.0% | 1.7% | 1.4% | 1.2% | 1.4% | |
| SG&A / Sales | 22.9% | 26.2% | 23.7% | 26.3% | 22.0% | |
| R&D / Sales | 14.9% | 22.7% | 14.1% | 11.2% | 14.3% | |
| Stock comp / Sales | 1.6% | 1.6% | 1.4% | 1.2% | 1.2% | |
| Intangibles / Total assets | 65.9% | 70.3% | 65.3% | 71.8% | 73.9% | |
| Days sales outstanding | 75d | 71d | 75d | 71d | 65d | |
| Days payables outstanding | 72d | 64d | 66d | 61d | 60d | |
| Operating cycle | 174d | 161d | 148d | 146d | 130d | |
| Cash conversion cycle | 102d | 97d | 82d | 84d | 70d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+29.4%EV / Sales ▲+15.1%EV / EBITDA ▲+5.7%EV / Op. cash flow ▲+4.702Earnings yield ▼-0.003
Profitability
Return on equity ▼-2.579Return on assets -0.000Return on invested capital ▲+0.041Return on capital employed ▲+0.127Operating ROA ▲+0.082Income quality ▲+0.115Tax burden ▼-0.511
Efficiency
Days sales outstanding ▲+4.384Days payables outstanding ▲+8.432Operating cycle ▲+13.376Cash conversion cycle ▲+4.944Capex / Sales ▲+0.003R&D / Sales ▼-0.078
Balance-sheet strength
Current ratio ▲+0.011Net debt / EBITDA ▼-0.558Working capital ▼-1060000000.000Invested capital ▼-6572000000.000Intangibles / Total assets ▼-0.044
Change over 5 years
Valuation
Market cap ▲+69.7%EV / Sales ▲+40.6%EV / EBITDA ▲+107.8%EV / Op. cash flow ▲+11.232Earnings yield ▼-0.038
Profitability
Return on equity ▼-2.041Return on assets ▼-0.047Return on invested capital ▲+0.001Return on capital employed ▲+0.061Operating ROA ▲+0.029Income quality ▲+2.531Tax burden ▼-0.248
Efficiency
Days sales outstanding ▲+10.330Days payables outstanding ▲+11.725Operating cycle ▲+44.157Cash conversion cycle ▲+32.432Capex / Sales ▲+0.006R&D / Sales ▲+0.006
Balance-sheet strength
Current ratio ▼-0.122Net debt / EBITDA ▲+0.787Working capital ▼-6961000000.000Invested capital ▼-25755000000.000Intangibles / Total assets ▼-0.080
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-05 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2026-05-01 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-12-18 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-12-08 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-10-31 | Lisa McClain | Sale | $1,001 - $15,000 |
| 2025-10-30 | Lisa McClain | Sale | $1,001 - $15,000 |
| 2025-10-30 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-08-04 | Ro Khanna | Purchase | $1,000 - $15,000 |
| 2025-08-04 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Sale | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-11 | Ritchie Torres | Sale (Full) | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-05-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-28 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-04-17 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-04-17 | Jefferson Shreve | Sale | $50,001 - $100,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-04-03 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-04-03 | Dwight Evans | Sale | $1,001 - $15,000 |
| 2025-04-01 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-03-17 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $50,001 - $100,000 |
| 2025-01-24 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-12-06 | Virginia Foxx | Purchase | $1,001 - $15,000 |
| 2024-11-20 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-26 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-07-02 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2024-04-10 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-23 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-08 | Michael C. Burgess | Sale (Full) | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-11-08 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-28 | Robert J. Wittman | Sale (Full) | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-09-06 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-30 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-14 | Michael C. Burgess | Sale (Full) | $15,001 - $50,000 |
| 2023-08-07 | Michael Patrick Guest | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-07-28 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-27 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-14 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $50,001 - $100,000 |
| 2023-07-06 | Michael C. Burgess | Purchase | $15,001 - $50,000 |
| 2023-06-29 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-26 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-05-26 | Zoe Lofgren | Sale | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-19 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-04-28 | Kathy Manning | Sale | $1,001 - $15,000 |
| 2023-04-28 | Kathy Manning | Sale | $1,001 - $15,000 |
| 2023-04-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-04-10 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2023-04-10 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-03-24 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-07 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-02-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-07 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-31 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-01-27 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-20 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-12 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-08-05 | Dwight Evans | Purchase | $1,001 - $15,000 |
| 2022-07-27 | Kathy Manning | Sale | $1,001 - $15,000 |
| 2020-11-16 | Richard W. Allen | Purchase | $15,001 - $50,000 |
| 2020-05-12 | Richard W. Allen | Purchase | $15,001 - $50,000 |
Recent news
- 2026-08-03 ABBV Q2 Earnings Call Balances Growth With Apogee Dilution AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.
- 2026-08-03 AbbVie: Strong Q2 And New Catalysts Keep Me Bullish On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its shares have fallen 6.2% despite strong Q2 earnings. Rinvoq sales grew 24.5% YoY and 19.2% quarter-over-quarter to about $2.53 billion in Q2.
- 2026-08-03 3 Top Dividend Stocks to Buy Before Their Next Payout Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means waiting another quarter to collect.
- 2026-08-03 First National Bank of Mount Dora Trust Investment Services Lowers Stock Position in AbbVie Inc. $ABBV First National Bank of Mount Dora Trust Investment Services lessened its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 6.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,721 shares of the company''s stock after selling 2,870
- 2026-07-31 Why AbbVie Stock Slumped Today It posted a second-quarter earnings report that raised some concerns. One was a miss on the consensus bottom-line estimate.
- 2026-07-31 AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
- 2026-07-31 AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and Rinvoq, Pipeline Advances Release Date: July 31, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (ABBV
- 2026-07-31 ABBV Beats on Q2 Earnings & Sales, Cuts ''26 EPS View, Stock Down AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
- 2026-07-31 Pre-Market Trading Up in Final Session of the Week Despite some mid-week turbulence, we''re trading fairly even with where we were as of mid-day Monday.
- 2026-07-31 AbbVie Q2 Earnings Call Highlights AbbVie NYSE: ABBV reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million.